Analysis of the main functions and efficacy of Epclusa and its effect in treating hepatitis C

EpclusaGeneric name: Sofosbuvir/Velpatasvir, Sofosbuvir/Velp atasvir) is an oral direct antiviral drug (DAA), mainly used to treat chronic hepatitis C virus (HCV) infection. As a combination drug, Jisandai acts on two key targets in the life cycle of HCV at the same time: Sofosbuvir (Sofosbuvir) is a NS5B polymerase inhibitor that can inhibit Inhibit virus RNA replication; Velpatasvir (Velpatasvir) is an NS5A inhibitor that can block virus replication and assembly, thereby achieving the purpose of rapidly reducing viral load.

Clinical studies have shown that Jisandai has broad-spectrum efficacy in patients with all HCV genotypes (1-6 types). There is no need to select drugs individually based on genotype, which is one of its significant advantages. Studies have shown that for untreated chronic HCV patients, a treatment course of 8-12 weeks can achieve 95% of results The above sustained virological response rate (SVR12) means that the virus RNA is still undetectable 12 weeks after the end of treatment. This high cure rate is also applicable to patients with mild to moderate liver fibrosis or even cirrhosis, showing strong efficacy and safety.

Jisandai also shows good results in patients with liver cirrhosis and special groups. For patients with mild to moderate cirrhosis, a standard 12-week course of treatment can achieve up to 95% of S VR rate, and patients with severe liver cirrhosis or liver insufficiency may need to extend the course of treatment or use it in combination with ribavirin (Ribavirin) to ensure the therapeutic effect. At the same time, Jisandai's oral administration is convenient, once-daily, and a single-pill combination preparation, which significantly improves patient compliance and reduces the risk of missed doses and dosage errors.

The safety of Jisandai has also been verified by multiple clinical trials. Common adverse reactions include headache, fatigue, nausea and insomnia, most of which are mild to moderate and tolerable. Compared with traditional interferon or ribavirin combination therapy, Gisanda significantly reduced the incidence of serious adverse events and did not cause obvious bone marrow suppression or psychiatric symptoms. For patients co-infected with HIV infection or receiving other commonly used drugs, Gisada also shows a lower risk of drug interactions, but doctors still need to evaluate potential interactions before use.

In general, Epclusa (Epclusa) has become an important choice for the treatment of chronic hepatitis C due to its broad spectrum, high cure rate and good safety. It is suitable for patients with various HCV genotypes, including those with liver fibrosis, cirrhosis and chronic diseases. Through 8 to 12 weeks of oral treatment, patients can achieve viral clearance, improve liver function and reduce the risk of liver fibrosis progression. Combined with the characteristics of convenient single-tablet administration and good tolerability, Gisanda not only improves treatment compliance, but also significantly improves patients' quality of life and long-term prognosis, making it one of the preferred options for hepatitis C treatment worldwide.

Reference materials:https://www.drugs.com/